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Abstract
Background: Paraneoplastic pemphigus (PNP) is a devastating autoimmune blistering disease, involving mucocutaneous
and internal organs, and associated with underlying neoplasms. PNP is characterized by the production of autoantibodies
targeting proteins of the plakin and cadherin families involved in maintenance of cell architecture and tissue cohesion.
Nevertheless, the identity of an antigen of Mr 170,000 (p170), thought to be critical in PNP pathogenesis, has remained
unknown.
Methodology/Principal Findings: Using an immunoprecipitation and mass spectrometry based approach, we identified
p170 as alpha-2-macroglobuline-like-1, a broad range protease inhibitor expressed in stratified epithelia and other tissues
damaged in the PNP disease course. We demonstrate that 10 PNP sera recognize alpha-2-macroglobuline-like-1 (A2ML1),
while none of the control sera obtained from patients with bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus
and normal subjects does.
Conclusions/Significance: Our study unravels a broad range protease inhibitor as a new class of target antigens in a
paraneoplastic autoimmune multiorgan syndrome and opens a new challenging investigation avenue for a better
understanding of PNP pathogenesis.
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Introduction
Paraneoplatic pemphigus (PNP) is an autoimmune multiorgan
syndrome associated with an underlying neoplasia [1,2,3].
Associated neoplasms include non-Hodgkin’s lymphoma, chronic
lymphatic leukaemia, Castleman disease, thymoma, and poorly
differentiated sarcomas. PNP patients characteristically develop a
severe polymorphous mucocutaneous eruption, features of which
resemble pemphigus vulgaris, erythema multiforme, Stevens-
Johnson syndrome and/or lichen. Involvement of internal organs,
such as pulmonary and gastrointestinal tracts, is also observed
[2,3,4]. Histologically, skin and mucosal lesions typically present
intraepithelial cleavage, suprabasal acantholysis, and interface
changes with necrotic and apoptotic keratinocytes [1,2,3,5,6].
Direct immunofluorescence (IF) microscopy studies disclose
intraepidermal and/or basement membrane zone deposition of
IgG and/or C3 complement component, whereas by indirect IF
microscopy PNP sera contain autoantibodies binding to stratified,
complex and simple epithelia, as well as to the myocardium
[1,2,3]. PNP patients’ autoantibodies typically bind to variable
proteins including the plakin family members desmoplakin I and
II, envoplakin, periplakin, plectin, and the bullous pemphigoid
antigen 230 (BP230, also termed BPAG1-e). Furthermore, in
analogy to pemphigus, desmoglein (Dsg) 1 and Dsg 3 are also
consistently recognized [1,7,8,9]. Finally, PNP autoantibodies
immunoprecipitate an unidentified protein of Mr170,000 (p170)
from keratinocyte extracts [1,7,8,9,10,11].
The pathological mechanisms underlying tissue damage in PNP
remain unclear. Different pathways have been involved to explain
the polymorphous clinical features and multiorgan involvement
[3]. Ample evidence indicates that autoantibodies against the
desmosomal components Dsg 1 and Dsg3, which are expressed in
stratified epithelia, play a central role in disrupting cell-cell
adhesion of keratinocytes leading to acantholysis and intraepider-
mal blistering [9]. The vast majority of PNP sera contain
autoantibodies directed against members of the plakin family.
These proteins serve as versative cytolinkers connecting the
intermediate filament cytoskeleton to distinct membrane sites,
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such as desmososomes and hemidesmosomes. However, despite
their ubiquitous expression, their role in disease initiation is
unlikely, since they are cytoplasmic proteins [8,11]. Furthermore,
though the majority of PNP sera also immunoprecipitate the p170
autoantigen, the search for the identity of this protein has proved
to be technically challenging [9,12,13]. Finally, CD8+ cytotoxic T
lymphocytes and other mononuclear cells are likely to contribute
to tissue damage resulting in keratinocyte necrosis and apoptosis
with a graft-versus-host disease-like phenotype in the skin [6,14].
Since identification of the target antigens is critical for a better
understanding of the pathophysiology of a devastating multiorgan
autoimmune syndrome such as PNP, we sought to characterize
p170 by using a combination of immunoprecipitation and mass
spectrometry analyses. We have identified A2ML1, a broad range
protease inhibitor expressed in the epidermis and other tissues
[15], as a novel autoantigen targeted by PNP autoantibodies.
Results
Analysis by MALDI-MS of p170 immunoprecipitated by a
PNP serum
We first performed a preparative immunoprecipitation of PNP
antigens from unlabelled cultured primary keratinocytes, differ-
entiated for 5 days using a previously well characterized PNP
serum sample [10]. Immunoprecipitated proteins were separated
by 1D-SDS-PAGE and stained by Coomassie blue. The stained
protein band migrating at Mr 170,000 was excised and subjected
to MALDI-MS analysis. Mass profiles of the tryptic peptides are
shown in Figure S1 and the mono-isotopic masses derived from
these profiles were used for the search in databases. We analyzed
the data using the Mascot program (http://matrixscience.com)
[16] to match the peptide mass fingerprint to two databases, NCBI
and MSDB. When blasted against the NCBI database, the top
score protein was alpha-2-macroglobuline-like-1 (A2ML1) (homo
sapiens), with a calculated molecular mass of 161 kDa
(gi|74271845, A8K2U0, Genbank accession No: AL832139). A
total of 43 out of 128 peptides from trypsinized p170 matched the
theoretical mass values of A2ML1 tryptic peptides. The 43 p170-
tryptic peptides covered 43% of the A2ML1 sequence with an
equal repartition of matches along the entire polypeptide. When
blasted against the MSDB database, the top score was obtained for
CAD48670, a protein of 165 kDa (sequence 1, homo sapiens,
covered by patent WO0229058). There were 44 p170-tryptic
peptides matching the theoretical peptide mass of trypsinized
CAD48670, covering 43% of the whole sequence. CAD48670
represents a putative splice variant of A2ML1. Finding A2ML1
(A8K2U0 and CAD48670) in two different databases prompted us
to hypothesize that p170 could be A2ML1.
Screening of PNP serum samples positive for p170
As the MALDI-MS results were obtained from p170 immuno-
precipiated by a single PNP serum, which was consumed for the
preparative immunoprecipitation, we first tested additional PNP
serum samples to further characterize p170. Sera obtained from
20 PNP patients were screened by conventional immunoprecip-
itation using biosynthetically radiolabeled extracts from cultured
differentiated human keratinocytes. Analysis of reduced immuno-
precipitation samples showed that most PNP sera targeted proteins
of Mr 250,000, 230,000, 210,000, and 190,000 corresponding to
desmoplakin I, BPAG1-e/BP230, desmoplakin II and/or envo-
plakin, and periplakin, respectively as described [3]. Furthermore,
10 out of the 20 PNP serum samples also immunoprecipitated
p170 (Figure 1A, serum 3 to 12). In our experiments, p170
displayed a Mr slightly higher than previously observed, above the
175,000 marker. This is most likely due to the use of different, pre-
stained molecular weight markers. The stoichiometry of the
precipitated proteins varied among the various PNP sera. In
contrast, two serum samples obtained from normal volunteers
(Figure 1A serum N1 and N2) did not significantly immunopre-
cipitate any proteins.
p170 is immunoprecipitated by PNP sera from the
culture medium of keratinocytes
Since A2ML1 is a secreted protein [15], we next assessed
whether p170 could be detected by immunoprecipitation with
PNP sera from the culture medium of radiolabeled differentiated
keratinocytes. Analysis of reduced immunoprecipitation samples
showed that PNP sera reactive against p170 from keratinocyte
Figure 1. Analysis of keratinocyte proteins immunoprecipitated by PNP auto-antibodies. Normal sera (N1 and N2) or PNP sera (1–12)
were used to immunoprecipitate proteins from radiolabelled keratinocyte extracts (A) or culture medium (B). Immunoprecipitates were denatured
under reducing conditions, separated on 6% SDS-PAGE, and autoradiographed. p170 migration level is indicated by a star. PNP sera 1 and 2
immunoprecipitated negligible amounts of p170. BP230, desmoplakin (DPI, DPII), envoplakin (EN) and periplakin (PP) migration levels are indicated in
panel A. In panel B, the non specific band also recognized by the control sera (N1, N2) with a slightly faster electrophoretic migration than p170 is
indicated (ns).
doi:10.1371/journal.pone.0012250.g001
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extracts (sera 3 to 12) also recognized a 170,000 protein from the
culture medium of keratinocytes (Figure 1B). The relative
intensity of the bands recognized by the various PNP sera from
culture media corresponded to that observed using keratinocyte
extracts. These results indicate that p170, like A2ML1, is a
secreted protein.
Recognition of p170 by PNP sera is sensitive to reducing
agents
So far, p170 has been exclusively detected by immunoprecip-
itation experiments, whereas immunoblotting studies using PNP
sera invariably failed to detect p170 [7]. A2ML1 is a cysteine-rich
protein with a predicted complex disulfide pattern [15], suggesting
that A2ML1 possesses a very constrained structure. We therefore
tested whether reducing conditions could play a role in the
recognition of p170 by PNP sera by Western blotting. p170-
positive PNP sera detected a protein of 170,000 from keratinocyte
extracts under non-reducing conditions, but not reducing
conditions (Figure 2A). The 170,000 protein was expressed more
strongly by differentiated than by undifferentiated keratinocytes.
This observation is in line with the reported increased expression
of A2ML1 in the granular cell layers of the epidermis [15].
Interestingly, the reactive protein band showed the same
electrophoretic migration of that recognized by the anti-A2ML1
antibody. The latter, however, bound to A2ML1 under both
reducing and non-reducing conditions (Figure 2B). p170-negative
PNP sera did not detect any 170,000 protein band under either
reducing or non-reducing conditions (Figure 2C). These results
suggest that PNP auto-antibodies recognize mainly conformation-
dependent epitopes, which are lost under reducing denaturing
conditions, explaining the lack of reactivity of PNP sera with p170
by Western blot analysis.
Anti-A2ML1 antibodies recognize p170
immunoprecipitated by PNP sera
The potential identity of p170 with A2ML1 was next analysed
by immunoblotting of the radioactive PNP immunoprecipitates
from keratinocyte extracts using anti-A2ML1 antibodies. A
protein migrating exactly at the same level as S35-labelled p170
was recognized by the anti-A2ML1 antibody. A good correlation
between the relative ratio of the signals obtained by Western
blotting using the anti-A2ML1 antibodies and those of the
autoradiogram (n = 10) was observed (Figure 3). In contrast,
when immunoprecipitates obtained either with p170-negative
PNP sera or normal sera were tested, no signal was detected using
anti-A2ML1 antibodies (Figure 3). These results strongly suggest
that p170 is A2ML1.
A2ML1 expressed in transfected HEK 293T cells is
recognized by p170-positive PNP sera
To further confirm the identity of p170 with A2ML1, we
generated a cDNA construct for eukaryotic expression of a c-myc-
tagged recombinant A2ML1 for both immunofluorescence and
immunoprecipitation studies. First, we transfected Human Em-
bryonic Kidney cells HEK 293T (American Type Culture
Collection) and carried out double immunofluorescence micros-
copy studies using the PNP sera (serum 1 to 12) and an anti-c-myc
antibody (representative sera are shown in Figure S2). The results
showed that p170-positive PNP sera (serum 3 to 12) specifically
labelled transfected cells expressing recombinant A2ML1-c-myc
with a fine granular cytoplasmic staining, while p170-negative
PNP sera (serum 1 and 2) and normal sera (serum N1 and N2) did
not (Figure S2).
Western blot analysis showed that HEK 293T cells transfected
with the construct encoding A2ML1-c-myc expressed and secreted
a protein of Mr 170,000 as expected (Figure S3). The secretion of
the c-myc-tagged A2ML1 in the culture medium was considered
as an indicator for the proper folding of the protein.
All p170-positive PNP sera (serum 3 to 12) immunoprecipitated
A2ML1-c-myc from transfected HEK 293 cells, whereas p170-
negative PNP sera (serum 1 and 2) did not (Figure 4A). The
relative band intensities of the immunoprecipitates obtained from
transfected cells using the different PNP sera paralleled those
obtained using extracts from radiolabeled cultured keratinocytes.
As control, sera from normal volunteers (n = 52), patients with
Figure 2. Denaturation conditions affect the recognition of
p170 by PNP auto-antibodies by immunoblotting. Extracts
(20 mg protein) from undifferentiated keratinocytes (lane 1), or
differentiated for 4 days (lane 2) and 8 days (lane 3) were denatured
in protein sample buffer containing or not 2-mercaptoethanol,
separated on 8% SDS-PAGE and transferred onto nitrocellulose
membrane for Western blot analysis using PNP serum 3 (A), anti-
A2ML1 antibody (B), and PNP serum 2 (C). Sera numbering corresponds
to that of Figure 1. Ponceau staining of the membranes is indicated as
loading control. p170 migration level is indicated by a star. Envoplakin
(EN) and periplakin (PP) migration levels are indicated.
doi:10.1371/journal.pone.0012250.g002
Figure 3. Anti-A2ML1 antibodies recognize p170 immunopre-
cipitated by PNP sera. Reduced samples immunoprecipitated from
radiolabelled keratinocyte extracts with normal (N1, N2) or PNP sera (1
to 12) (see Fig. 1) were separated on 8% SDS-PAGE and transferred onto
nitrocellulose membrane. This membrane was autoradiographed (A)
and analyzed by immunoblotting using anti-A2ML1 antibodies (B).
doi:10.1371/journal.pone.0012250.g003
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pemphigus vulgaris (n = 24), pemphigus foliaceus (n = 4) and
bullous pemphigoid (n = 28) did not immunoprecipitate A2ML1-
c-myc from transfected HEK 293T cells (representative samples
are presented Figure 4B). Together, these data provide strong
support that p170 is A2ML1.
Adsorption studies demonstrate that p170 corresponds
to A2ML1
To provide additional evidence that A2ML1 corresponds to
p170, we carried out immunoprecipitation studies using PNP sera
that were adsorbed with recombinant A2ML1- FLAG-His8,
expressed in transfected HEK 293T and bound to Ni2+-resin. As
control, serum samples were treated with a Ni2+-resin loaded with
mock-transfected cell extracts. To evaluate the selectivity of
depletion, we first analyzed the pattern of immunoblotted proteins
from undifferentiated and differentiated primary human keratino-
cyte extracts separated under non-reducing conditions
(Figure 5A). Adsorbed PNP sera showed no or significantly
reduced reactivity with p170, compared to mock-adsorbed PNP
sera. Importantly, the binding of adsorbed sera to other PNP
autoantigens was not affected, indicating that anti-p170 antibodies
were selectively depleted by the A2ML1-FLAG-His8-affinity resin.
We then carried out immunoprecipitation studies using differen-
tiated primary human keratinocytes (Figure 5B). The immuno-
precipitates obtained either with mock-adsorbed or adsorbed PNP
sera (n = 9) were probed by Western blotting using the anti-
A2ML1 antibody. Immunoprecipitation of p170 was either
completely or at least strongly reduced when adsorbed sera were
used, compared to mock-adsorbed sera. Immunoblotting of the
same immunoprecipitates with anti-envoplakin antibodies [17]
confirmed that the adsorption was selective for anti-A2ML1
antibodies in PNP sera. These results indicate that PNP
autoantibodies bind to common epitopes present on both p170
and A2ML1.
Finally, we also assessed the effect of the depletion of the anti-
p170 antibodies by immunofluorescence microscopy of skin
cryosections using the PNP serum no. 9 with strong and
apparently selective reactivity with p170 (Figure S4). The
mock-adsorbed PNP serum stained the upper and superficial
epidermal cell layers, the pattern of which was similar to that
obtained with the anti-A2ML1 antibody (Figure S5), as
previously described [15]. In contrast, there was almost no
labelling of the upper epidermal layers when the adsorbed PNP
serum sample was used.
Mapping of A2ML1 domains recognized by PNP
autoantibodies
To gain insight about potential mechanisms by which auto-
antibodies against A2ML1 may affect its function, we carried out a
domain mapping study. A2ML1 was divided into two portions,
based on the similarity between A2M and A2ML1 and A2ML1
predicted disulfide pattern [15], domains (http://smart.embl-
heidelberg.de, email: ) and secondary structures (GOR4 program
developed by NPS@: network Protein Sequence Analysis) [18,19].
HEK 293T cells were transfected to express c-myc tagged recom-
binant forms of either the NH2-terminal half (A2ML1
1–889) or the
COOH-terminal half of A2ML1 (A2ML1 990–1454). The former
encompasses the bait domain important for protease targeting,
whereas the latter contains the thiolester and low density
lipoprotein receptor-related protein 1-binding domains [15,20].
We assessed proper folding of these proteins by controlling their
secretion (Figure S3). Nine out of ten PNP sera reacted with
A2ML1 1–889, while only three bound to the A2ML1 990–1454, as
revealed by immunoblotting of the immunoprecipitates with anti-
myc antibodies (Figure 6). One serum did not show any
reactivity. These results indicate that PNP autoantibodies mainly
target the NH2-half of A2ML1.
Figure 4. PNP sera immunoprecipitate recombinant A2ML1
expressed in HEK 293T. PNP (A, 1–12), normal (A and B, N1-N10),
pemphigus vulgaris (PV1-PV4) and bullous pemphigoid sera (B, BP1-
BP4) were used to immunoprecipitate proteins from extracts of HEK
293T cells transfected with pISb05, encoding recombinant A2ML1-c-
myc. PNP sera numbering corresponds to that of Figure 1. Reduced
immunoprecipitates were separated on 8% SDS-PAGE and analyzed by
immunoblot using anti-c-myc antibody. p170 migration level is
indicated by a star.
doi:10.1371/journal.pone.0012250.g004
Figure 5. Adsorption of PNP sera with recombinant A2ML1
prevents PNP serum reactivity with p170. Nickel resin loaded with
HEK 293T extracts expressing (ADS) or not (MOCK) A2ML1-Flag-HIS8 was
incubated with PNP sera (diluted 1/10). Sera numbering corresponds to
that of Figure 1. (A) Treated sera were used to carry out the Western
blot analysis of undifferentiated (ND) or differentiated for 8 days (Diff)
human primary keratinocyte extracts (20 mg/lane), separated after non-
reducing denaturation on 6% SDS-PAGE. The migration position of
p170 is marked by a star. (B) Treated sera were used to immunopre-
cipitate proteins from 8-day-differentiated primary human keratino-
cytes. Reduced immunoprecipitates were separated on 6% SDS-PAGE,
and analyzed by Western blotting using anti-A2ML1 antibody (A2ML1).
The same membrane was reprobed with anti-envoplakin (EN). The one
or two bands corresponding to envoplakin (17) are marked by a square.
The sequential probing of the membrane without stripping explains the
signal at p170 level when probed with the anti-envoplakin antibody.
doi:10.1371/journal.pone.0012250.g005
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Discussion
The characterization of p170 antigen recognized by PNP sera
has proved to be a challenging task. Our study unravels the
identity of this protein targeted by PNP autoantibodies as the
protease inhibitor A2ML1. This conclusion is based on several
lines of evidence: 1) the tryptic mass profile of the immunopre-
cipitated p170 has a significant match with that expected for
A2ML1; 2) p170 is recognized by anti-A2ML1 antibodies and can
be immunoprecipitated from culture media of human keratino-
cytes, in the same manner as A2ML1; 3) PNP sera immunopre-
cipitate recombinant A2ML1 from cell extracts, whereas binding
to A2ML1 was never observed with sera obtained from normal
volunteers (n = 52) as well as patients with autoimmune bullous
diseases of the skin (n = 56); 4) p170-reactive PNP sera selectively
labelled transfected cells expressing recombinant A2ML1; 5) pre-
incubation of p170-reactive PNP sera with recombinant A2ML1
selectively abrogated reactivity of the PNP sera with p170 by
immunoblot or immunoprecipitation, and further reduced the
labelling of the epidermal granular cell layers, where A2ML1 is
predominantly expressed. Together, our data unravel a novel class
of proteins targeted by autoantibodies in patients suffering from
this devastating multiorgan disease.
A2ML1 is a broad range protease inhibitor belonging to the
A2M protease inhibitor family. It binds different classes of
proteases and inhibits their activity or reduces the substrate
spectrum by a ‘‘trap mechanism’’ in which the inhibitor covalently
binds the protease and creates a sterical hindrance within the
active site [15]. During this process, the conformational change
releases the COOH-terminal extension of A2ML1, which then
can be recognized by lipoprotein receptor-related protein 1
(LRP1) receptor to allow the internalization and clearance of the
complex protease inhibitor-protease [20]. A2ML1 is expressed in
many tissues such as the epidermis, thymus, and testis, while
A2ML1 ESTs reported in UniGene mainly arise from normal and
tumoral stratified epithelia [15]. Furthermore, the EST expression
profile (Hs.620532, NCBI Unigene, EST profile viewer) suggests
the presence of high transcript levels of A2ML1 in oesophagus,
mouth, pharynx, intestine, and muscle. Interestingly, comparison
of the sequence of A8K2U0 and CAD48670, which displays the
highest score with p170 tryptic mass profile suggests the existence
of splice variant(s) of A2ML1.
The exact function of A2ML1 is not yet defined. By analogy to
A2M which has been proposed to be an element of the innate
immunity [21] A2ML1 may participate in defense mechanisms by
binding to inflammatory cytokines, growth factors and by
targeting a broad range of proteases [15]. Furthermore, A2ML1
is likely to be directly implicated in the maintenance of epidermal
homeostasis based on its ability to form covalent complexes with
the kallikrein KLK7 in vitro [15], a protease involved in proteolysis
of intercellular structures and in desquamation process [22].
Our findings provide an explanation for the failure to identify
p170 so far. First, the full length cDNA sequence of A2ML1 in
humans was reported in 2004 [23,24], while its functional
characterization was carried out in 2006 [15]. Therefore,
indexation and theoretical profiling of A2ML1 in databases have
been only available in the past few years. Second, the biochemical
properties of A2ML1 constitute an additional challenge for its
identification. A2ML1 is a secreted glycoprotein with a secondary
structure constrained by multiple disulfide bridges [15]. Further-
more, over-heating of A2ML1 in reducing-denaturing conditions
results in its cleavage in two polypeptides of 120 kDa and 60 kDa
([15] and personal observations), which reduces the signal intensity
at the expected electrophoretic migration. Finally, our analyses
demonstrate that PNP anti-A2ML1 autoantibodies recognize
conformational epitopes, explaining the two-decade failure to
detect p170 by Western blot under denaturing conditions [7]. It is
likely that production of A2ML1 in an eukaryotic expression
system ensuring proper folding and posttranslational modifications
facilitates its detection.
There is no ortholog of human A2ML1 in mouse, rendering the
direct in vivo demonstration of the pathogenicity of anti-A2ML1
antibodies by passive transfer studies impossible. Accordingly,
gene targeting experiments are not feasible. Furthermore, no
hereditary human disorder has been mapped to the A2ML1 gene
locus so far. Nevertheless, there are a number of indirect
observations providing support to the idea that auto-antibodies
against p170 are involved in the initiation or the perpetuation of
tissue damage, since: 1) in a significant number of reported PNP
patients, including patient 9 of the present study, autoantibody
reactivity against p170 is found alone or with few additional
reactivities, at least by immunoprecipitation [12,13]; 2) PNP sera
binding to p170 can be detected already at an early stage of the
disease [12,13]; 3) A2ML1 is not only expressed in skin but also in
other organs affected in PNP (Hs.620532, NCBI Unigene, EST
profile viewer); 4) acquired or genetic defects of protease inhibitors
may cause a variety of muco-cutaneous diseases with systemic
symptoms [22,25,26,27]. For example, mutations in SPINK5 gene
encoding the serine protease inhibitor lympho-epithelial Kazal-
type inhibitor (LEKTI) cause Netherton syndrome [26] associated
with chronic skin inflammation and skin barrier defects. LEKT1 is
thought to regulate kallikrein activity [28,29].
The impact of auto-antibodies on biochemical properties and
function of A2ML1 could not be determined, due to difficulties to
obtain sufficient amounts of purified A2ML1. However, two
studies document the negative impact of the binding of
autoantibodies to protease inhibitors. First, in acquired autoim-
mune angioedema, autoantibody binding to C1-inhibitor (C1-inh)
facilitates its cleavage by its target proteases and result in a non-
functional truncated circulating form of C1-inh [30]. Second, in
rheumatoid arthritis, auto-antibodies to serpin E2 diminish the
inhibitory activity of serpin on urokinase plasminogen activator
serine protease [31]. In analogy, anti-A2ML1 antibodies may
either destabilize A2ML1 or prevent its interaction with its target
proteases, inflammatory cytokines or its receptor LRP1 and
thereby affect the activity of extracellular proteases or amplify
tissue damage. In this context, it should be noted that our domain
mapping results show that the NH2-terminal portion of A2ML1 is
Figure 6. The NH2-half of A2ML1 is preferentially recognized
by PNP antibodies. PNP sera (1–12) and normal serum (N1) (see Fig. 1)
were used to immunoprecipitate recombinant A2ML11–889-c-myc (A) or
A2ML1990–1454-c-myc (B) expressed in transfected HEK293T cells.
Immunoprecipitates were separated by SDS-PAGE after reducing (A)
or non-reducing (B) denaturation to avoid the co-migration of the
protein of interest with the antibodies used for the immunoprecipita-
tion and analyzed by Western blotting using anti-c-myc antibody. As a
control A2ML1990–1454-c-myc was immunoprecipitated in parallel with
anti-c-myc antibodies (c-myc) and run together with the other samples.
Exposure time of the c-myc lane was 2 sec versus 7 min for the others.
doi:10.1371/journal.pone.0012250.g006
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almost systematically targeted by PNP autoantibody. Since this
domain is implicated in the recognition of target proteases, PNP
autoantibodies to A2ML1 may prevent the formation of protease-
protease inhibitor complex. The identification of physiologically
important targets of A2ML1 will be extremely useful to further
understand the pathological involvement of anti-A2ML1 autoan-
tibodies.
Dissecting the mechanisms underlying the association of PNP
with distinct neoplasia is probably key for our understanding of the
onset of autoimmunity in PNP. In the case of Castleman disease,
tumor resection results in remission of PNP symptoms [2,32,33].
Castleman, thymoma or follicular dendritic cell sarcoma cells have
been shown to produce autoantibodies reactive with various PNP
autoantigens [33,34]. Noteworthy, reactivity with p170 is found in
up to 76% of patients with PNP associated with Castleman disease
[32,35]. Future systematic studies with prospective cohorts of
patients and detailed analysis of the immunological profile are
needed to assess whether presence of anti-A2ML1 autoantibodies is
associated with a particular PNP phenotype and organ involvement
as well as a specific type of neoplasia. In this context, the
retrospective nature of our study precluded a reliable analysis.
Nevertheless, based on the tissue distribution profile of A2ML1 and
its lack of expression in pulmonary epithelium [36], it is unlikely that
autoantibodies to A2ML1 contribute to bronchiolitis obliterans and
respiratory failure, a frequent cause of death in PNP.
Our study thus puts an end to a relentless search for p170 and
identifies PNP as a first example of an autoimmune multiorgan
syndrom in which autoantibodies to a protease inhibitor might
contribute to tissue damage by aggravating and precipitating
inflammation.
Materials and Methods
Ethics Statement
Normal human serum samples were obtained from voluntary
blood donors of the local regional Swiss blood bank. Written
consent for public use was provided.
Patients’ sera were obtained from patients managed in
Switzerland (PNP n= 1, other bullous disease n = 56), France
(PNP n= 12), Japan (PNP n= 7) and Germany (PNP n= 1). All
sera were collected as a part of standard care and with the oral
consent of the patients according to the local ethical rules. Sera
were thus already available before this research was started. Since
this is a non-interventional study and characterization of sera’
reactivity is accepted and expected by the patients as normal
diagnostic procedure, no written consent was required according
to the local Swiss, French, German and Japanese ethics
committees. Furthermore, since this research study did not involve
intervention or interaction with the included individuals and the
information collected during the study was not individually
identifiable and not readily ascertained by the investigators,
ethical review was not requested also in line with recent
recommendations of the Office for Human Research Protections.
Human sera
Sera were obtained from 20 patients with clinically, histolog-
ically and immunopathologically typical PNP [2,3]. Sera were also
obtained from patients with bullous pemphigoid (n = 28), pem-
phigus vulgaris (n = 24), pemphigus foliaceus (n = 4) and normal
subjects (healthy blood donors, n = 52).
Cell culture and transfection
Primary human keratinocytes (Invitrogen) were grown in
Keratinocyte-SFM medium, supplemented with EGF and pitui-
tary extracts (Invitrogen), penicillin, streptomycine. Differentiation
was induced by adding calcium 1 mM, isoproterenol 1 mM and
hydrocortisone 0.4 mg/ml to the growth medium [37]. Human
Embryonic Kidney cells HEK 293T (American Type Culture
Collection) cells were grown in DMEM supplemented with foetal
bovine serum (FBS) 10%, penicillin, and streptomycine. HEK
293T cells were transfected according to the calcium phosphate
method [38]. When HEK 293T cell culture medium was analyzed
for protein secretion, the cells were briefly rinsed in PBS 15 hours
after transfection and grown in DMEM medium without FBS for
two days.
In vivo labeling of keratinocytes
Primary human keratinocytes (foreskin) were purchased from
Invitrogen. In vivo labelling of keratinocyte proteins was performed
as previously described [10]. Briefly, after 4 days of differentiation,
keratinocytes were incubated for 1 h in DMEM medium without
methionin/cystein (Invitrogen) and then overnight in DMEM
medium without methionin/cystein supplemented with 100 mCi/
ml of 35S-Met/35S-Cys (Hartmann Analytics, Germany).
Cell extracts
Cells were lyzed in Tris-HCl 50 mM pH 7.5, NaCl 150 mM,
NP-40 1%, protease inhibitor cocktail (Sigma). The insoluble
fraction was removed by centrifugation, and the supernatant was
used for either immunoprecipitation or, after denaturation in
protein sample buffer with or without 2-mercapto-ethanol, for
separation on SDS-PAGE (6%) and Western blotting.
Immunoprecipitation
Patient sera (30 ml) or anti-myc antibodies (4 mg) were incubated
with protein A-Sepharose resin (GE Healthcare), in Tris-HCl
50 mM pH 7.5, NaCl 150 mM, protease inhibitor cocktail during
2 hours on ice. After discarding the unbound fraction, cell lysates
were incubated with the resin 2 hours on ice, and then extensively
washed with Tris-HCl 50 mM pH 7.5, NaCl 150 mM, protease
inhibitor cocktail. Proteins bound to the resin were eluted in
protein sample buffer (with or without 2-mercaptoethanol).
In-gel digestion of p170 for MALDI mass spectrometry
analysis
The preparative 1D-SDS-PAGE gel, used to separate the
immunoprecipitated proteins, was stained with Coomassie Bril-
liant Blue R250. The band containing the 170,000 protein was
excised, and transferred into a fresh quartz vessel. The gel pieces
were washed alternately three times with 10 ml digestion buffer
(10 mM NH4HCO3, pH 7.8) and 10 ml modified digestion buffer
(10 mM NH4HCO3/acetonitrile 1:1). Afterwards the gel pieces
were shrunken in the vacuum and reswollen with 2 ml protease
solution (0.05 mg/ml trypsin, Promega, USA). Digestion was
performed for 10–12 h at 37uC. Afterwards 8 ml of 5% formic
acid was added to the gel piece twice (successively) and the
peptides were extracted for 15 min in a sonication bath. The
pooled supernatant was mixed with 1 ml of C18-beads (Poros 10
R2- chromatography beads, 5 mg/ml in methanol, PerSeptive
Biosystems, USA) and completely dried in a vacuum concentrator.
Concentrated samples were taken in 1 ml MALDI matrix (a-
cyano-hydroxycinnamic acid in acetonitrile/0.1% TFA, 0.7:0.3).
MALDI mass spectrometry and data analysis
MALDI peptide mass fingerprint analysis was done on a Reflex
IV mass spectrometer (Bruker Daltonics,Germany). Matrix
containing C18-bead bound peptides were transferred to a MALDI
A2ML1 Is p170 PNP Autoantigen
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12250
sample plate. Dried samples were washed with 1 ml of 0.1% TFA.
Analysis was done with the following settings: a target voltage of
20 kV, an acceleration electrode voltage of 13.5 kV, a reflectron
voltage of 21.6 kV and a reflectron detector voltage of 1.6 kV.
PMF spectra were interpreted using the Mascot program
(http://matrixscience.com) [16]. The chosen parameters were:
human NCBI and MSDB database, tryptic cleavage, mass
tolerance 61.5 Da, expected mass of the protein 170 kDa. The
number of maximal missed cleavages was set to 1.
Cloning
Clone DKFZp686O1010Q (AccNo AL832139) containing
A2ML1 full length cDNA was purchased from ImaGenes
(Germany). The vectors pISb05, pISb07, pISb08, pISb09 were
derived from pcDNA3 vector (Invitrogen), and encode chimeric
versions of A2ML1cDNA from clone DKFZp686O1010Q.
pISb05 encodes A2ML1 fused to a c-myc-tag at its COOH-
terminus, which was prepared in sequential steps. The c-myc-tag
was introduced by PCR amplification using 59GACTAGTCT-
CACAGGTCCTCCTCTGAGATCAGCTTCTGTTCTGCTT-
CACAGAGATCAGAATACTG and 59CTTGCCAAATATGC-
CACTAC primers. A strong Kozak sequence was also inserted by
PCR using 59CCCAAGCTTGCCGCCACCATGTGGGCT-
CAGCTCCTTCTAG and 59GAGAAGCCAAGGGAAACCTG
primers. pISb07 is derived from pISb05, and encodes A2ML1
fused to a Flag-tag and a His(8)-tag at its C-terminus: this double
tag was introduced by PCR using 59 TGGTGAGTCAGGGTC-
TATGG and 59TCCGGGCCCTCAATGATGATGATGAT-
GATGATGATGACCGGTACGCTTGTCATCGTCATCCT-
TGTAGTCTGCTGCTTCACAGAGATCAGAATACTG pri-
mers. pISb08 encodes A2ML1 (residues 1–889) (A2ML11–889)
fused to a c-myc tag. This vector was derived from pISb05 and
prepared using primers 59ATGGGACAGACGTTTCTCTG and
59ATAGGGCCCTCACAGGTCCTCCTCTGAGATCAGCT-
TCTGTTCTGCTGCGGGAACAAACCCCTTCTG to insert
the c-myc tag sequence. pISb09 encodes A2ML1 (residues 890–
1454) (A2ML1890–1454) fused to a C-myc tag, and was derived
from pISb05. A strong Kozak sequence and a secretion signal
peptide were introduced by PCR using 59CCCAAGCTT-
GCCGCCACCATGTGGGCTCAGCTCCTTCTAGGAATG-
TTGGCCCTATCACCAGCCATTGCA CAAAAGGGCCGA-
AGTGACAC and 59GTAGAGGTTGGTCGTGGAGG prim-
ers. The sequence of the portions of cDNA prepared and amplified
by PCR were verified by sequencing (Mycrosynth, Switzerland).
Preparation of protein from cell culture medium
Debris were removed from culture medium by centrifugation
and proteins were precipitated with 10% v/v trichloroacetic acid
1 h on ice, the pellet was collected by centrifugation 10 min at
16,000 g, washed with acetone and resuspended in Laemmli
sample buffer.
Protein reducing and non reducing denaturation and
separation
Protein reducing denaturation was performed in Laemmli
buffer [39] incubated 3 min at 95uC degrees. For the non reducing
denaturation, 2-mercaptoethanol was omitted. SDS-PAGE sepa-
ration was carried out as previously described [39].
Western blotting
Gels were transferred onto nitrocellulose membrane in Tris-
glycine buffer, ethanol 10%, 0.1%SDS, for 1 h at 100 V. Western
blot analyses were performed in standard conditions. Antibodies
were diluted as follows: anti-A2ML1 1/250 (Abnova), anti-Flag 1/
500 (Sigma-Aldrich), anti-c-myc 1/500 (Santa Cruz Biotechnol-
ogy).
Serum adsorption
Soluble extracts from HEK 293T cells transfected with A2ML1-
FLAG-His8 were prepared as described above using a pH 8 buffer
and were incubated with Nickel-resin (Sigma-Aldricht) 1 h on ice,
and the resin was subsequently submitted to extensive washing
with Tris-HCl 50 mM, pH 8, NaCl 200 mM, NP40 1%, protease
inhibitor. The equilibrated resin was incubated overnight with
100 ml serum diluted 10 fold in the same buffer with protease
inhibitors. The same procedure was performed using untrans-
fected HEK 293T cell extracts for the control experiment. The
supernatant was then used for Western blot analysis, immunopre-
cipitation or immuno-fluorescence.
Immunofluorescence
All antibodies were diluted in PBS 1% BSA. HEK 293T cells
were fixed with paraformaldehyde 4%, permeabilized with Triton
X-100 0.1%, blocked with BSA 1%, and incubated with Anti-c-
myc (1/150) and patient sera (1/150) during 1 h. The Alexa-fluor
488-anti-rabbit and Alexa-fluor-588-anti-human secondary anti-
body (Invitrogen) were diluted 1/300 and incubated 1 h at room
temperature. Nuclei were stained with DAPI. Cryostat sections (4–
5 mm) of human breast skin were air-dried, fixed for 10 min in 4%
ice cold acetone and rehydrated in Tris–buffered saline with 0.1%
saponin. Double immunofluorescence was performed by serially
incubating sections with anti-A2ML1 (1/50) and anti-envoplakin
CR5 (1/100) antibody for 1 h followed by incubation with Alexa-
fluor-568-anti-mouse (1/100) and Alexa-fluor-588-anti-rabbit (1/
100). Nuclei were stained with DAPI. Immunofluorescence with
adsorbed sera was performed incubating the adsorbed and mock-
adsorbed sera (1/2.5) 1 h, and then Alexa-fluor-568 anti-human
antibody (Invitrogen).
Supporting Information
Figure S1 Monoisotopic mass profiles of p170 tryptic digest
(MALDI-TOF mass spectrometry).
Found at: doi:10.1371/journal.pone.0012250.s001 (9.64 MB EPS)
Figure S2 PNP sera selectively recognize HEK 293T cells
expressing recombinant A2ML1-c-myc. Cells transfected with
pISb05, encoding A2ML1-c-myc were labelled with both anti-c-
myc antibody (green) and human sera (red): normal (A) or PNP 2,
4 and 7 (B, C and D). Nuclei were stained with DAPI (blue). Sera
numbering corresponds to that of Figure 1. White scale bar:
100 mm.
Found at: doi:10.1371/journal.pone.0012250.s002 (2.14 MB EPS)
Figure S3 Expression and secretion of recombinant A2ML1
proteins in HEK 293T cells. Extracts (20 mg) of untransfected HEK
293T cells (lanes 1) or transfected with pISb07 (lanes 2), encoding
A2ML1-Flag-His8, were separated on 10% SDS-PAGE, and
analyzed by Western blotting using anti-A2ML1 or anti-Flag
antibody. B. Culture medium (400 ml) of 293T cells non transfected
(lane 1), or transfected with pISb05 (lane 2), pISb08 (lane 3), pISb09
(lane 4) encoding A2ML1-c-myc, A2ML11-889-c-myc, and
A2ML1890-1454-c-myc, respectively were TCA-precipitated, sep-
arated on 10% SDS-PAGE and analyzed by Western blotting using
anti-c-myc antibody. Lane 2, the band at 60,000 is likely a COOH-
terminal degradation product of A2ML1 occurring during
denaturation of the sample under reducing conditions.
Found at: doi:10.1371/journal.pone.0012250.s003 (1.95 MB EPS)
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Figure S4 Adsorption of PNP-serum 9 with recombinant
A2ML1 reduces immunofluorescence staining in the upper layers
of epidermis. PNP serum 9 mock-adsorbed (A) or adsorbed with
recombinant A2ML1 (B) were used to probe sections of human
breast skin. The reactivity of the secondary anti-human antibodies
against human breast skin section is shown (C): the signal detected
in the dermis and the upper cornified edge of the epidermis is
therefore non-specific to the patient serum reactivity. The specific
reactivity due to A2ML1 is expected in the upper layers of the
epidermis, areas indicated by the white arrows. As a reference
A2ML1 pattern in human breast skin is shown. Nuclei were
stained with DAPI (blue). White scale bar: 100 mm.
Found at: doi:10.1371/journal.pone.0012250.s004 (2.19 MB EPS)
Figure S5 A2ML1 is expressed in the upper layers of human
skin. Sections of human breast skin were labeled with CR5 anti-
envoplakin antibody (A, green) and anti-A2ML1 antibody (B, red).
The patterns obtained with the secondary anti-rabbit (C, green)
and anti-mouse antibody (D, red) are shown. Nuclei were stained
with DAPI. White scale bar: 100 mm.
Found at: doi:10.1371/journal.pone.0012250.s005 (1.74 MB EPS)
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